Prognostic alternative mRNA splicing in lung adenocarcinoma.

ABSTRACT:

Background

Alternative splicing (AS) of mRNA has emerged as a promising biomarker for various tumors, playing a crucial role throughout nearly all stages of tumor progression and influencing the tumor immune microenvironment (TIME). Our study was designed to develop an AS-based signature for accurate prognosis prediction in lung adenocarcinoma (LUAD) patients, to delineate the associated immune cell landscape, and to pinpoint promising drug targets.

Methods

Prognostic alternative splicing events (PASEs) were identified through univariate Cox regression analysis of RNA-Seq data from The Cancer Genome Atlas (TCGA). These PASEs were incorporated into a least absolute shrinkage and selection operator-Cox proportional hazards model to develop a prognostic signature. Experimental

SUBMITTER: Su P 

PROVIDER: S-EPMC12669014 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature